GI-targeted ROCK inhibitor for fibrostenotic Crohn’s disease in phase 1 study February 29, 2024 AutoBot News 0 Yesterday, (February 28), a clinical-stage biotechnology company, Redx, announced that the first participant has been dosed in a phase 1 clinical trial for RXC008.